With reference to the notice of the Board Meeting dated October 23, 2026, we hereby inform that the Board of Directors at its meeting held on October 31, 2026 has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026.

Advanced enzymes WhereENZYMEisLife AdvancedEnzymeTechnologiesLtd. CIN:L24200MH1989PLC051018 SunMagnetica,A'wing,5thFloor,LICServiceRoad,Louiswadi,Thane(W)-400604,India Tel:+91-22-41703200,Fax:+91-22-25835159 Email:info@advancedenzymes. com, www.advancedenzymes. October 31, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Dear Sir, Subject: Outcome of Board Meeting held on October 31, 2026 Ref: ISIN: INE837H01020 With reference to the notice of the Board Meeting dated October 23, 2026, we hereby inform that the Board of Directors at its Meeting held on October 31, 2026 (commenced at 10:45 a.m. and concluded at 11:35 a.m.) has inter alia, transacted the following business:  Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026. Please find enclosed herewith the above mentioned Financial Results along with the Limited Review Report from the Statutory Auditors as Annexure – I.  Analyzed the requests received from the promoter group members for their reclassification from promoter group category to public category shareholders, pursuant to Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The details of the promoter group members who had requested for reclassification along with the views of the Board on those requests is enclosed as Annexure – II. The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com This is for your information and for public at large. Thanking you, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head – Legal Encl.: As above Factory:PlotNo.A-61/62,MIDCMalegaon,Tal.Sinnar,Dist.Nashik-422113.Maharashtra.India.Tel.:+91-9970100750/+91-2551-230044,Fax:+91-2551-230816 Annexure-I MSK A & Associates LLP HO 602,Floor6,RahejaTitanium (Formerlyknown asMS K A & Associates) WesternExpressHighway,Geetanjali RailwayColony, RamNagar, Goregaon(E) CharteredAccountants Mumbai400063,INDIA Tel:+912269740200 Independent Auditor’s Review Report on consolidated unaudited financial results of Advanced EnzymeTechnologies Limitedfor thequarter andyear to datepursuant totheRegulation 33 of the SEBI(ListingObligations andDisclosureRequirements)Regulations,2015,asamended TotheBoardof Directors of AdvancedEnzymeTechnologiesLimited 1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as ‘the Holding Company’), its subsidiaries, (the Holding Company andits subsidiaries together referred to as the ‘Group’) and its share of the net loss after tax and total comprehensive loss of its associate for the quarter ended September 30, 2026and theyear to-dateresultsfor theperiodfrom April01,2026toSeptember 30, 2026 (‘theStatement’) attachedherewith, beingsubmittedby theHoldingCompany pursuant to the requirements of Regulation33 of theSecurities and ExchangeBoard of India (ListingObligations and DisclosureRequirements) Regulations, 2015,asamended (‘theRegulations’). 2. This Statement, whichis the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rulesissuedthereunder (‘Ind AS 34’) and other recognisedaccountingprinciples generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on theStatement basedonour review. 3 Weconducted our review of theStatementinaccordancewith theStandardonReview Engagements (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would becomeawareof allsignificant matters that might beidentifiedinan audit. Accordingly, we do not expressanaudit opinion Wealsoperformedproceduresinaccordancewiththecircular issuedby theSecuritiesandExchange Boardof Indiaunder Regulation33 (8) of theRegulations, totheextent applicable. 4. ThisStatementincludestheresultsof theHoldingCompanyandthefollowingentities: Sr No Nameof theEntity Relationship with theHolding Company 1 AdvancedBio-AgroTechLimited Subsidiary 2 AdvancedEnzytechSolutionsLimited WhollyOwnedSubsidiary AdvancedEnzymesUSA,Inc. (‘AEU’) WhollyOwnedSubsidiary AdvancedSupplementaryTechnologiesCorporation WhollyOwnedSubsidiaryof CalIndiaFoodsInternational(‘CAL’) WhollyOwnedSubsidiaryof RegisteredOffice: 602,RahejaTitanium,WesternExpressHighway,Goregaon(East),Mumbai-400063,Maharashtra,India Tel:+912269740200|LLPIN:ACT-3789 Ahmedabad I Bengaluru | Chandigarh | Chennai I Coimbatore| Goa | Gurugram | Hyderabad | Kochi | Kolkata Pune www. mska. in MSK A fit Associates LLP (Formerly known asMS K A & Associates) CharteredAccountants EnzymeInnovation Inc WhollyOwnedSubsidiary of 7 JCBiotechPrivateLimited (‘JCB’) Subsidiary 8 ScitechSpecialitiesPrivateLimited Subsidiary 9 AdvancedEnzymesEurope B V (‘AEEBV’) WhollyOwnedSubsidiary EvoxxTechnologiesGmbH WhollyOwnedSubsidiaryof AEEBV 11 SaiganeshEnzytechSolutionsPrivateLimited Subsidiary StaryaLabs Inc WhollyOwnedSubsidiaryof AdvancedNutrazymePrivateLimited WhollyOwnedSubsidiary (with effect fromJuly04,2025) Raywatt SolarEnviroPrivateLimited Associateof JCB (witheffect from August10,2026) 5 Based on our reviewconductedandprocedures performed asstatedin paragraph 3 aboveandbased on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement preparedinaccordance with the recognitionandmeasurement principles laiddownin Ind AS 34 and other recognised accountingprinciples generally acceptedin India hasnot disclosed theinformation required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed,or thatitcontainsanymaterialmisstatement. 6. We did not review theinterim financial information of four subsidiaries included in the Statement, whose interim financial information (before consolidation adjustment) reflects total assets of Rs. 2,263.07million as at September 30, 2026 and totalrevenues of Rs. 650.59 million and Rs. 1,252.39 million, totalnet profit after tax of Rs. 71.04millionandRs. 95.94millionand totalcomprehensive income of Rs. 70.14millionand Rs. 95.07million for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026 respectively, and cash outflows (net) of Rs. 11.13 million for the period from April 01, 2026 to September 30, 2026, as considered in the Statement These interim financial information have been reviewed by the other auditors whose reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures includedin respect of these subsidiaries, is based solely on the reports of theother auditorsandtheproceduresperformedbyusasstatedinparagraph 3 above Our conclusion is not modified in respect of the above matter with respect to our reliance on the workdonebyandreport of theother auditors 7 One subsidiary is lo [Showing first 8,000 characters — download PDF for full document]